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technical aspects of incorporating robotic assistance and the periopera-
tive outcomes. 
Methods
Patients with adequate cardiopulmonary reserve to tolerate lobectomy 
for clinical stage I NSCLC or other pathologic tumors that were periph-
eral and conﬁned to the lung were considered eligible for VATS lobec-
tomy. At our institution the procedure is performed using two 1 – 1.5 
cm access incisions and a ≤ 4 cm non-rib-spreading utility incision 
with intrathoracic visualization achieved via thoracoscope exclusively. 
Initial thoracic exploration is conducted with conventional thoracos-
copy in order to verify resectability and to establish the three standard 
VATS lobectomy access incisions. Once the incisions have been made, 
the da Vinci® robot is brought into position, the surgical instruments are 
introduced under direct thoracoscopic vision, and the operating surgeon 
moves to the surgeonís console. Robotic assistance is deﬁned as use of 
the da Vinci® Surgical System during a VATS lobectomy for individual 
dissection, isolation, and ligation of the pulmonary hilar structures, as 
well as mediastinal lymph node dissection. 
Informed consent for robotic assistance during VATS lobectomy was 
obtained. Data on patient characteristics, operative details and post-
operative recovery were collected in a prospective database approved 
by the institutional review board and analyzed retrospectively. All 
complications were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 3.0 (CT-
CAE 3.0)(http://ctep.cancer.gov/reporting/ctc.html). 
Results
Between November 2002 and May 2006 there were 63 consecutive 
patients who underwent attempted robotic-assisted VATS lobectomy 
employing the da Vinci® Surgical System. The patient characteristics 
are listed in the Table. Most of the lesions were located in the up-
per lobes (44/63, 70%) with right upper lobe tumors being the most 
common (28). The vast majority of our patients had NSCLC (60/63, 
95%), two patients had typical carcinoid tumors, and one had a primary 
pulmonary lymphoma. Those with NSCLC all were clinical stage IA 
preoperatively. Eleven patients (17%) had no tissue diagnosis and 
underwent initial VATS and wedge resection in the same setting. 
VATS lobectomy using robotic assistance was completed in 58 (92%) 
patients. Conversion to thoracotomy was required in 5 patients (8%). 
Three patients were converted for minor bleeding, two from cautery 
injuries to a segmental pulmonary artery in the course of dissection 
and one during isolation of the superior pulmonary vein. None of these 
patients required blood transfusion intraoperatively or postoperatively. 
One patient required conversion secondary to loss of single lung 
isolation and one underwent thoracotomy for excessive adhesions and 
inﬂammatory nodal disease. The Table shows the perioperative results. 
Median total operative time was 284 minutes (range 185 – 460). Me-
dian intrathoracic operative time was 210 minutes (range 143 – 350). 
Of note, the median total and intrathoracic operative time for the last 10 
cases were 210 minutes (range 185 – 301) and 186 minutes (range 151 
– 240), respectively. Every type of lobectomy was done, and mediasti-
nal lymph node dissection was performed in each instance. The median 
number of lymph node stations dissected in patients undergoing suc-
cessful robotic-assisted VATS lobectomy was 5.0 (range 2 – 7). 
For the patients with NSCLC the overwhelming majority had adenocar-
cinoma, and 87% (52/60) had pathologic stage I disease. The median 
size of the lesions pathologically was 2.0 cm (0.8 – 5.0). Eight patients 
were pathologic stage II, and only 2 patients had unsuspected stage IIIA 
disease. All patients underwent R0 resection. 
The median chest tube duration for the entire group was 3.0 days 
(range 2 – 19), and the median length of stay was 4.0 days (range 2 
– 20). The complication rate for all patients was 24% (15/63). The most 
common complication was supraventricular tachycardia. The major-
ity of complications were minor (CTCAE grade 2). One patient with 
a history of coagulopathy had postoperative hemorrhage requiring 
re-exploration with no clear source of bleeding identiﬁed. Two patients 
suffered postoperative myocardial infarctions: one underwent emer-
gency cardiac catheterization and stent placement while the second had 
successful medical management. There were no in-hospital deaths, and 
the 30-day mortality rate was 0%.
Conclusions
Robotic-assistance for VATS lobectomy is feasible and safe. The pri-
mary utility of robotic-assistance for VATS lobectomy is in the superior 
articulation of the instruments. Increasing experience reduces operative 
times. 
Table. Patient characteristics and perioperative results (n=63)
Median age 69.0 (12 - 85)
M:F 27:36
Tumor location
RUL 28
LUL 16%
LLL 6
RLL 11
RML 2
Median tumor diameter 2.0 (0.8 - 5.0)
Tumor histology
NSCLC 60
Typical carcinoid 2
MALT 1
Pathologic stage (NSCLC, n=60)
T1N0M0 (IA) 42
T2N0M0 (IB) 10
T1N1M0 (IIA) 6
T2N1M0 (IIB) 2
T1-2N2M0 (IIIA) 2
Median total operative time (mins) 284 (185 - 460)
Median intrathoracic op time (mins) 284 (185 - 460)
Median chest tube duration (days) 3.0 (2 - 19)
Median length of stay (days) 4.0 (2 - 20)
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Management of Small Cell Lung Cancer in 2007
Although small cell lung cancer (SCLC) makes up a smaller propor-
tion of all lung cancers than it did 25 years ago, it remains a common 
cause of cancer mortality that requires more clinical and basic research 
than is currently underway. Progress in the management of small cell 
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lung cancer (SCLC)) has been slow and treatment paradigms have 
changed little over the past 20 years. The traditional reasons cited for 
lack of progress include a) utility of local therapies such as surgery and 
radiotherapy is limited by early development of systemic metastases, 
b) local relapses remain common despite initial radiotherapy respon-
siveness. c) Drug resistance remains problematic despite innovations 
in cytotoxic chemotherapy d) identiﬁcation of new agents with novel 
therapeutic targets has been difﬁcult. 
Staging
Accurate staging determines the intent and structure of the treatment 
program. The principles of staging of SCLC are rooted in studies from 
another generation. The Veterans Administration Lung Group staging 
system that divides patients into either limited or extensive stages has 
been durable for SCLC because of its simplicity and reliable prognos-
tic value. Limited-stage SCLC (LSCLC) is deﬁned as tumor conﬁned 
to one hemothorax and the regional lymph nodes, whereas extensive 
stage small cell lung cancer (ESCLC) is deﬁned as disease beyond 
these bounds. The original operational deﬁnition of limited disease 
was tumor quantity and conﬁguration that could be encompassed by 
a “reasonable” radiotherapy treatment volume. Because long-term 
survival is uncommon (5 to 7%) when chemotherapy alone is used to 
treat LSCLC, the “reasonable radiotherapy port” rule continues to be 
of practical importance in the assembly of combined-modality therapy 
programs that increase the long-term survival rate to over 20%. SCLC 
typically spreads early with 60% to 70% of patients having extensive 
stage disease (ESCLC) with metastases outside the limited-stage deﬁni-
tion. Although patients with “regional” extensive stage disease such 
as pleural effusions and contralateral hilar and supraclavicular nodes 
may be given combined modality therapy with a small chance of cure, 
ESCLC is typically treated with palliative intent. In addition to limited 
stage, other pretreatment prognostic factors associated with a favorable 
outcome in Cox regression analyses include, good performance status, 
a low alkaline phosphatase level, a normal lactate dehydrogenase and 
female gender. Standard staging procedures include CT images of 
the chest and abdomen, CT/MRI of the brain and a radionuclide bone 
scan. Although widely used, the impact of PET scanning on staging 
and treatment has not yet been deﬁned in large published data sets or 
practice guidelines. 
Systemic Treatment
SCLC has been of particular interest to medical oncologists because 
this disease supposedly is “highly sensitive to chemotherapy treat-
ment”. Although response rates to chemotherapy are higher for SCLC 
than non-small cell lung cancer, the absolute survival statistics for pa-
tients with metastatic disease receiving cytotoxic drugs are similar for 
both conditions. Median survival times for patients receiving standard 
chemotherapy regimens for stages IIIB/IV NSCLC and extensive stage 
SCLC are both in the 8-10 month range and the proportion surviving 2-
years is about 10-15%. Despite higher response rates, the median time 
required for chemotherapy resistant clones to cause a fatal outcome is 
similar for advanced SCLC and NSCLC.
Many permutations and variations of protocols containing ﬁve drugs 
(cyclophosphamide, doxorubicin, vincristine, etoposide, and cisplatin) 
or their analogues have been reported and a number of regimens have 
been used in phase III studies. Although a clearly superior combination 
never emerged, the power of chemotherapy was clearly improved with 
multi-agent chemotherapy. In 1975, Einhorn and colleagues combined 
cyclophosphamide, doxorubicin and vincristine (CAV) and produced 
not only high response rates but complete responses were observed in 
20% of cases. Interest in the combination of etoposide and cisplatin 
(EP) was stimulated after it was shown to produce tumor regression in 
patients whose cancers had progressed following initial drug treatment 
with a cyclophosphamide-based regimen. The consistent performance 
of EP or carboplatin and etoposide in clinical trials plus the bonus of its 
compatibility with radiotherapy has made it a standard of such durabil-
ity that it persists as the treatment of choice.[1] 
Manipulations that intensify the delivery of chemotherapy with 
increased dose-intensity, increased number of agents and high dose 
chemotherapy with stem cell support have not worked. It has not been 
convincingly possible to demonstrate that delivery of more than four 
cycles of a platinum-etoposide regimen improves outcome. 
With respect to the introduction of new chemotherapy agents, a phase 
III trial from Japan[2] was stopped early when the combination or 
irinotecan and cisplatin demonstrated survival superiority to the EP 
combination in ESCLC. Median survival was typical in the EP arm 
at 9.4 months versus 12.8 months for the irinotecan-treated arm (P = 
0.002). At 2 years, the percentage of patients surviving was 19.5% 
versus 5.2%. However, a phase III trial of a different schedule (day 
1,8) of irinotecan and cisplatin generated identical outcomes compared 
to the EP regimen.[3] A conﬁrmatory phase III trial by the Southwest 
Oncology Group (S0124) is designed to reproduce the clinical data of 
the Japanese trial in a larger population (620 patients) and also inves-
tigate pharmacogenomic endpoints predictive of toxicity or efﬁcacy of 
irinotecan and cisplatin. A pall of pessimism exists that combinations 
including topoisomerase inhibitors are capable of displacing EP as stan-
dard therapy for ESCLC. 
Other new drugs such as pemetrexed and amrubicin are active and 
undergoing testing in combination with a platinum agent in ESCLC. 
However, like advanced NSCLC, it is increasingly unlikely that the 
plateau in the power of treatment for SCLC will be changed with the 
introduction of an analogue of a folate antagonist or another anthracy-
cline. The two drug combination of etoposide and cisplatin is likely to 
remain the standard of care for cytotoxic therapy. 
With respect to targeted therapy for SCLC, at the moment, the most in-
terest exists for drugs that target angiogenesis. Pujol et al. have reported 
survival extension with maintenance thalidomide in a randomized 
trial.[4] Conﬁrmatory trials are underway and thalidomide analogues 
are under investigation. At the 12th World Conference in Korea, data 
will be presented on phase II studies that have added bevacuzimab to 
combination chemotherapy for SCLC.
Combined Modality Therapy for Limited Stage SCLC
Although investigation of thoracic irradiation timing is reported in 7 
randomized trials of varying structure, size and vintage, sequence and 
timing continues to generate controversy. Recently, a meta-analysis 
performed according to the Cochrane Collaboration Guidelines exam-
ined randomized controlled clinical trials comparing different timing 
of chest radiotherapy in patients with LSCLC.[5] Early chest irradia-
tion was deﬁned as beginning within 30 days after the start of chemo-
therapy. Seven randomized trials were eligible. A weighted estimate 
of the typical treatment effect across studies was computed for 2-year 
survival data as well as the 5-year survival data, local control and tox-
icities. The odds ratio (OR) was used as the effect measure. Taking all 
seven studies into account, the overall survival at 2 years or at 5 years 
was not signiﬁcantly different between early or late chest radiotherapy 
(OR for 2 years 0.84, 95% CI 0.56-1.28, OR at 5-years 0.80, 95% CI 
0.47-1.38). When the one trial that delivered non-platinum chemo-
therapy concurrently with chest radiation[6] was excluded, the OR was 
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signiﬁcantly in favor of early chest radiotherapy at 5 years (OR: 0.64, 
95% CI 0.44-0.92, P=0.02). Considering studies with an overall treat-
ment time of chest radiation of less than 30 days, the 5-year survival 
was even better (OR:0.56, 95%CI: 0.37-0.85; P = 0.006). As expected, 
esophageal, pulmonary and pulmonary toxicity was worse with initial 
concurrent chemoradiation but severe leukopenia was more frequent in 
patients receiving late chest radiotherapy (P = 0.0004). 
Although a conclusion in favor of early concurrent chemoradiation 
for LSCLC is not deﬁnitive, analysis of relevant subsets of the data 
is rational. Exclusion of non-platinum chemotherapy is supported by 
a meta-analysis showing superiority of SCLC regimens containing 
cisplatin and a conclusive phase III trial showing better survival of 
the EP regimen compared to a cyclophosphamide/anthracycline-based 
regimen.[7] Early thoracic irradiation cannot be expected to perform 
well unless it is coupled with a chemotherapy regimen compatible with 
concurrent radiotherapy and efﬁcacious enough to improve control of 
micro-metastases outside the thoracic irradiation volume. 
By evidence, the standard dose and treatment for LSCLC is 45 Gy 
delivered in three weeks in 30 fractions of 1.5 Gy, administered concur-
rently with cisplatin plus etoposide.[8] In Canada, 40 Gy in three weeks 
is still widely used.[9] We really do not know that longer treatments 
or higher doses are better for local control or survival, but we are now 
able to deliver doses up to 70 Gy in 7 weeks without a clear signal that 
higher doses are superior. 
Prophylactic Cranial Irradiation
Patients with cancer control outside the brain have a 60% actuarial risk 
of developing brain metastases within 2 to 3 years after starting treat-
ment. In a meta-analysis of 7 randomized trials evaluating the value of 
prophylactic cranial irradiation, the risk of developing central nervous 
system metastases was reduced by >50%.[10] Additionally, 3-year 
overall survival of complete responders (predominately LSCLC) was 
20.7% with PCI versus 15.3% in the control group. 
The selection of an optimal dose for PCI that would lead to further 
decreases in brain metastasis incidence with minimal toxicity is the 
subject of an ongoing international trial addressing the question of the 
optimal PCI dose for the prevention of metastases. A standard dose of 
25 Gy in 10 fractions is being compared to 36 Gy in 18 fractions or 36 
Gy in 24 twice daily fractions. PCI should not be given with systemic 
chemotherapy because of increased toxicity. 
Conclusion
Although small cell lung cancer (SCLC) makes up a smaller propor-
tion of all lung cancers than it did 25 years ago, it remains a common 
cause of cancer mortality that requires more clinical and basic research 
than is currently underway. Trials of newer chemotherapy variations 
have failed to produce a regimen that is clearly superior to the two drug 
combination of etoposide and cisplatin, which remains the standard of 
care for both limited and extensive stage SCLC. Paradoxically advanc-
es in this systemic disease have come from radiotherapy innovations 
for limited SCLC including addition of thoracic irradiation to systemic 
chemotherapy, more intense thoracic irradiation, early integration of 
thoracic irradiation with systemic chemotherapy and prophylactic 
cranial irradiation.[11] 
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In oncological patients with solid tumor, treatment is most often guided 
by histology and staging which are also the main eligibility criteria 
for clinical trials. However, it is known for decades that there might 
be considerable heterogeneity within the same histological type and 
that this heterogeneity leads to variations for response to treatment 
and survival with sensitivity to a given therapy being restricted to a 
subgroup of patients. If this heterogeneity is unknown and disregarded 
in the design of a clinical trial, it can have harmful consequences on the 
power of a trial to detect a beneﬁt for the investigational treatment, the 
loss of power depending on the differential treatment effect in sensitive 
and in non sensitive patients as well as on the true proportion of sen-
sitive patients, sensitive patients who are not necessarily accurately rep-
resented in phase II trials (1). Tumor biology might be responsible for 
the heterogeneity and progress in the knowledge of tumor biology did 
allow the development of molecularly targeted agents. This complicates 
drug development and, in particular, the design of randomised phase III 
clinical trials.
In some situations, at the time of initiating a phase III trial, we may be 
lacking from reliable and/or quick assays to select sensitive patients 
and, consequently, traditional trials with broad eligibility criteria are 
still used despite the fact that a true treatment effect on the sensitive 
patients only may be diluted by the absence of effect (or worse by a 
deleterious effect) in non sensitive patients. At the end of the trial, 
a stratiﬁed analysis can be done for the sensitivity status although a 
stratiﬁed randomisation for the sensitivity status might be wished to 
avoid random differences in the proportion of sensitive patients in both 
arms. Freidlin and Simon (2) proposed an attractive adaptive design 
combining in the same time the development of a classiﬁer and the 
conduct of a clinical trial for testing an overall effect of the investiga-
tional treatment and a speciﬁc effect in a subgroup of sensitive patients, 
